Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Review · June 06, 2024

Real-World Outcomes of Second-Line Therapies for HR+/HER2− LABC/mBC After First-Line CDK4/6 Inhibitor Therapy

BMC Cancer


Additional Info

BMC Cancer
Systematic literature review of real-world evidence for treatments in HR+/HER2- second-line LABC/mBC after first-line treatment with CDK4/6i
BMC Cancer 2024 May 23;24(1)631, V Lambert, S Kane, B Howidi, BN Nguyen, D Chandiwana, Y Wu, M Edwards, IA Samjoo

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading